Friday, Novavax Inc (NASDAQ: NVAX) entered a co-exclusive licensing agreement with Sanofi SA (NASDAQ:SNY) for COVID-19 and flu-COVID-19 combination vaccines.

The terms of the agreement include:

• A co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and India, Japan, and South Korea where Novavax has existing partnership agreements).

• Novavax has a sole license to its adjuvanted COVID-19 vaccine for use in combination with Sanofi’s flu vaccines, while Novavax retains the right to and is developing its own COVID-19-Influenza Combination vaccine candidate.

• A non-exclusive license to use Novavax’s adjuvanted COVID-19 vaccine in combination with non-flu vaccines.

• A non-exclusive license to use the Matrix-M adjuvant in vaccine products.

Novavax will receive an upfront payment of $500 million and up to $700 million in development, regulatory, and launch milestones, up to $1.2 billion.

Starting in 2025, Sanofi will book sales of Novavax’s adjuvanted COVID-19 vaccine and will support certain R&D, regulatory, and commercial expenses.

Novavax will receive tiered double-digit percentage royalty payments on sales by Sanofi.

Sanofi will be responsible for developing and commercializing any novel flu-COVID-19 combination vaccine containing a Sanofi flu vaccine.

Outside of the collaboration, each party may develop and commercialize their own flu-COVID-19 vaccines and adjuvanted products at their own cost.

Novavax is entitled to additional launch and sales milestones opportunities of up to $200 million plus mid-single digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax’s Matrix-M adjuvant technology.

In addition, Sanofi will take a minority (less than 5%) of approximately $70 million equity investment in Novavax.

Novavax reported a first-quarter EPS loss of $(1.05), down from a loss of $(3.41) a year ago, beating the consensus of $(1.06)

The company reported sales of $93.86 million, up from $80.95 million a year ago, missing the consensus of $101.16 million.

Novavax removes the going concern notice.

Novavax is prepared to initiate an additional cost reduction program to reduce 2025 R&D and SG&A expenses to below $500 million, a portion of which it expects to be reimbursed by Sanofi under the agreement, reflecting over $225 million reduction beyond prior stated targets.

Guidance: Novavax updates 2024 combined revenue and Sanofi Agreement Payments Of $970 million-$1.17 billion versus prior guidance of $800 million-$1 billion.

Price Action: NVAX shares are up 121% at $9.88 during the premarket session at last check Friday.

Photo: Marco Verch from Flickr.

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.